As per MRFR analysis, the US Polyp Biopsy Market Size was estimated at 91.14 (USD Million) in 2023. The US Polyp Biopsy Market Industry is expected to grow from 98.7(USD Million) in 2024 to 746.9 (USD Million) by 2035. The US Polyp Biopsy Market CAGR (growth rate) is expected to be around 20.2% during the forecast period (2025 - 2035).
The US Polyp Biopsy Market is experiencing significant trends driven by an increasing awareness of colorectal cancer and the rising incidence of polyps detected during routine screenings. The US Preventive Services Task Force recommends regular screening for colorectal cancer, contributing to a surge in diagnostic procedures, including polyp biopsies.
The rising prevalence of obesity, sedentary lifestyles, and dietary factors are key market drivers, as these conditions are often linked to higher risks of colorectal polyps. Additionally, advancements in endoscopic technologies and techniques are enhancing the effectiveness and accuracy of polyp biopsies, making them more appealing to healthcare providers and patients alike.
Opportunities in the US Polyp Biopsy Market can be further explored through the development of minimally invasive procedures and the integration of artificial intelligence in pathological analysis to improve diagnostic accuracy. With a focus on patient-centered care, there is also potential for novel biopsy technologies that minimize discomfort and promote quicker recovery times.
Patient education campaigns aimed at increasing screening adherence and participation can play a crucial role in promoting early detection and intervention. Recent trends include increased governmental and institutional support for colorectal cancer awareness campaigns, which are essential in driving screening rates. This reflects a larger societal push towards preventive healthcare and early detection methods.
Furthermore, there is a notable shift towards personalized medicine in colorectal health, meaning that biopsy results are increasingly used to tailor treatment plans based on individual patient profiles. All these elements indicate a dynamic environment in the US Polyp Biopsy Market, focusing on improving patient outcomes and advancing technology in the field.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The United States has seen a significant rise in the incidence of colorectal cancer, which is a primary factor driving the US Polyp Biopsy Market Industry. The American Cancer Society reported that in 2021 alone, approximately 104,270 new cases of colon cancer were diagnosed, and evidence suggests this trend is likely to continue with an annual increase of nearly 1% among adults over 50 years of age.
This surge in colorectal cancer cases necessitates more frequent and advanced biopsy procedures to detect polyps early and prevent cancer progression. Moreover, established organizations such as the Centers for Disease Control and Prevention (CDC) are actively promoting screening measures and guidelines, further catalyzing the growth of the polyp biopsy market in the US.
These efforts underscore the increasing demand for effective diagnostic solutions, directly influencing the market's future prospects and expansion.
The US Polyp Biopsy Market Industry is experiencing growth due to advancements in diagnostic technologies, including high-definition endoscopy and molecular diagnostics. The improvement in these technologies enhances the accuracy and efficiency of polyp detection and biopsy procedures. According to the National Institute of Health, high-definition endoscopic techniques have increased the detection rate of small polyps by over 30% compared to traditional methods.
This transition to advanced technologies encourages healthcare providers to opt for more effective biopsy solutions, driving market growth. The overall emphasis on precision medicine and personalized diagnostics also aligns with the increasing budget allocations for Research and Development (R&D) interventions in the US healthcare system, further propelling the demand for innovative biopsy techniques.
Rising public awareness about colorectal health and preventative screenings is significantly boosting the US Polyp Biopsy Market Industry. Campaigns led by organizations such as the American Cancer Society and the CDC advocate for routine screening, particularly among populations at risk. National statistics indicate that approximately 70% of adults aged 50 and above have been screened for colorectal cancer, reflecting an increase in awareness over the past decade.
Furthermore, enhanced healthcare policies fostering early detection initiatives underscore the critical role of awareness programs in promoting screening, which in turn drives demand for polyp biopsies. This cultural shift towards preventive healthcare is translating into increased utilization of biopsy services across the country.
The US Polyp Biopsy Market, classified by Type, encompasses a variety of procedures critical for accurate diagnosis and screening of polyps. One dominant procedure in this segment is Colonoscopy, which plays a significant role in colorectal cancer prevention by enabling the detection and removal of polyps before they can develop into cancerous lesions.
With rising awareness about colorectal cancer and its prevention, this method has seen a substantial increase in adoption rates across the US. Likewise, Colposcopy-Directed Biopsy serves as another essential component, particularly in gynecological examinations, where it allows for effective screening of cervical abnormalities. The focus on early detection of cervical cancer contributes to this procedure's importance and its growing utilization among healthcare professionals.
Additionally, Esophagogastroduodenoscopy is utilized for upper gastrointestinal examinations, helping identify and address polyps in the esophagus and stomach, which are critical given the increasing prevalence of gastrointestinal disorders among the US population. The procedure not only aids in diagnosis but also allows for therapeutic interventions.
Furthermore, Laryngoscopy, although less prevalent than the previously mentioned procedures, remains vital for examining laryngeal structures and identifying potential polypoid lesions, particularly in patients with voice disorders or chronic hoarseness. Keeping in mind the diverse utility and importance of these biopsy types, the US Polyp Biopsy Market showcases a robust framework that addresses various health concerns.
Each type plays a unique role in the broader scope of polyp detection and management, underlining the collective effort toward improved patient outcomes and increased screenings as part of preventive healthcare initiatives in the region. This market growth is significantly influenced by the rising demand for early intervention, technological advancements, and increasing healthcare expenditure in the US.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Distribution Channel segment of the US Polyp Biopsy Market plays a crucial role in facilitating access to necessary medical procedures and products. The market has seen significant growth due to the rising prevalence of colorectal cancer and increasing awareness about early detection among the US population.
Online Sales Channels have emerged as a prominent force, offering convenience and accessibility for patients seeking at-home tests, thus fostering greater patient engagement in their health. Retail Pharmacies are essential as they provide a familiar touchpoint for patients, allowing them to obtain products recommended by healthcare professionals conveniently.
Additionally, other channels contribute to the distribution landscape, catering to specific needs and niches within the market. As health trends evolve, consumers are increasingly turning towards both online shopping and traditional retail for their healthcare needs, reflecting broader patterns in consumer behavior and the impact of digital transformation on the healthcare industry.
Various advancements in technology and logistics for distribution further support the overall market growth, addressing challenges like product availability and efficient delivery. This diversification in the distribution channel is critical for reaching a wider audience and enhancing the overall efficacy of colon health management in the country.
The US Polyp Biopsy Market has shown significant growth across various End User segments, primarily driven by the increasing prevalence of colorectal cancer among the population. Hospitals and Clinics play a crucial role in diagnostics and treatment, as they are often the first healthcare points where patients receive care.
This segment is characterized by advanced medical facilities that can provide comprehensive endoscopic services, making it vital for timely polyp detection and management. Diagnostic Centers are also pivotal, offering specialized services in diagnostic imaging and pathology, thus supporting faster and accurate diagnoses.
They contribute significantly to efficiency in detecting polyps and are often equipped with cutting-edge technologies. Academic and Research Organizations enhance the sector by driving innovations and advancements in biopsy techniques and methodologies. They play a fundamental role in developing new protocols and treatments through extensive Research and Development, ultimately contributing to improved patient outcomes.
Overall, these segments combine to form a robust framework that supports the US Polyp Biopsy Market, addressing both the needs of patients and the advancements in medical technology.
The US Polyp Biopsy Market is characterized by a competitive landscape that reflects a growing emphasis on technological advancements and innovative solutions aimed at improving patient outcomes. This market has gained traction due to the increasing incidence of colorectal cancer, which accelerates the demand for effective screening and early detection measures.
Medical professionals are continually seeking state-of-the-art biopsy tools and methodologies that enhance diagnostic accuracy and procedural efficiency. The competitive insights within this sector reveal the dynamics of market players striving for dominance through product differentiation, strategic partnerships, and adherence to regulatory standards that ensure both quality and safety in medical devices.
Hologic has established a strong foothold in the US Polyp Biopsy Market, driven by its commitment to innovation and excellence. The company is well-known for its advanced imaging systems and minimally invasive biopsy technologies that empower healthcare providers to conduct precise and efficient procedures. Hologic’s strengths lie in its robust product portfolio, which encompasses a range of biopsy devices designed to cater to various clinical needs.
The company’s focus on research and development facilitates the introduction of cutting-edge solutions that not only comply with regulatory requirements but also address the evolving needs of healthcare professionals. Moreover, Hologic’s strategic alliances and collaborations with leading healthcare institutions further enhance its market presence, allowing for broader distribution and adoption of its products.
C.R. Bard plays a significant role in the US Polyp Biopsy Market, recognized for its extensive range of medical devices, particularly in the biopsy segment. The company's key offerings include a variety of biopsy needles and accessories that are designed for greater accuracy and patient comfort. C.R. Bard benefits from a strong reputation for quality and reliability, which has fortified its position in a competitive marketplace.
The company has also engaged in strategic mergers and acquisitions to expand its product line and enhance its market presence, allowing for the integration of innovative technologies into its offerings. This proactive approach has enabled C.R. Bard to maintain its competitive edge while continuing to address the specific demands of medical professionals and patients in the US. By focusing on delivering superior products and leveraging its operational strengths, C.R. Bard has successfully positioned itself as a key player within the US Polyp Biopsy Market.
The US Polyp Biopsy Market has seen notable developments recently, particularly with advancements in biopsy technology and increasing demand for colorectal cancer screening. In December 2022, Medtronic launched a new device aimed at enhancing the accuracy of polyp removal, thereby supporting improved patient outcomes.
Moreover, Hologic has been focusing on expanding its product line, introducing innovative solutions for gastroenterology applications in the realm of polyp detection. Growth in market valuation has been reported across key players such as C.R. Bard and Boston Scientific, reflecting a heightened focus on R&D and effective marketing strategies to boost their presence in this critical healthcare segment.
Notably, in February 2023, Abbott Laboratories announced its acquisition of a digital pathology firm, which is expected to enhance its capabilities in guiding polyps detection and diagnosis. In the past two years, the US market has experienced a surge in public awareness regarding the importance of colorectal screenings, leading to an increase in procedures and devices being utilized for effective diagnosis and treatment.
This awareness underscores the shift towards preventive healthcare measures within the US medical landscape.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 91.14(USD Million) |
| MARKET SIZE 2024 | 98.7(USD Million) |
| MARKET SIZE 2035 | 746.9(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 20.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Hologic, C.R. Bard, EndoChoice, Medline Industries, Medtronic, Boston Scientific, Abbott Laboratories, Conmed Corporation, Olympus Corporation, Stryker Corporation, Cook Medical, Pentax Medical, Johnson and Johnson, Intuitive Surgical |
| SEGMENTS COVERED | Type, Distribution Channel, End User |
| KEY MARKET OPPORTUNITIES | Increased colorectal cancer screenings, Advanced biopsy technologies adoption, Rising prevalence of polyps, Enhanced reimbursement policies, Growing awareness and education programs |
| KEY MARKET DYNAMICS | increasing incidence of colorectal cancer, advances in biopsy technologies, rising awareness about early detection, growing aging population, supportive government regulations |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Polyp Biopsy Market is expected to be valued at 98.7 million USD in 2024.
A compound annual growth rate of 20.2% is expected for the US Polyp Biopsy Market from 2025 to 2035.
By 2035, the US Polyp Biopsy Market is anticipated to reach a value of 746.9 million USD.
The colonoscopy segment is expected to have the largest market share, valued at 39.0 million USD in 2024.
The colposcopy-directed biopsy segment is projected to reach 190.0 million USD by 2035.
Major players include Hologic, Medtronic, and Boston Scientific among others in the US Polyp Biopsy Market.
The esophagogastroduodenoscopy segment is expected to be valued at 150.0 million USD in 2035.
The laryngoscopy segment is valued at approximately 14.7 million USD in 2024.
Growing awareness and advancements in biopsy technologies are key growth drivers for the US Polyp Biopsy Market.
Challenges include regulatory hurdles and the need for skilled professionals in the US Polyp Biopsy Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
